Compare OSPN & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSPN | KMDA |
|---|---|---|
| Founded | 1991 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 524.6M | 460.3M |
| IPO Year | 2000 | 2013 |
| Metric | OSPN | KMDA |
|---|---|---|
| Price | $14.55 | $7.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $16.67 | $14.00 |
| AVG Volume (30 Days) | ★ 506.0K | 44.4K |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | ★ 4.53% | 3.08% |
| EPS Growth | ★ 28.77 | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $243,180,000.00 | N/A |
| Revenue This Year | $3.22 | $13.94 |
| Revenue Next Year | $3.16 | $9.84 |
| P/E Ratio | $47.77 | ★ $24.59 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.07 | $6.50 |
| 52 Week High | $18.13 | $9.35 |
| Indicator | OSPN | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 64.92 | 42.91 |
| Support Level | $12.09 | $7.35 |
| Resistance Level | $16.17 | $8.63 |
| Average True Range (ATR) | 0.55 | 0.13 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 49.78 | 41.86 |
OneSpan Inc is a provider of information technology security solutions for banking and financial services and application security markets. The company build secure, seamless, and trusted digital experiences through two solution portfolios: Cybersecurity solutions engaged in protecting identities, securing mobile apps, and safeguarding access through high-assurance authentication, threat intelligence, fraud prevention, and robust mobile app protection, defending users, devices, and applications against sophisticated attacks, while Digital agreement solutions focuses on streamlining workflows with secure e-signatures, identity verification, and smart digital forms, built to enable speed, compliance and other customer experiences.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.